Kyri Van Hoose

Kyri Van Hoose is a seasoned and collaborative finance and accounting professional with over 20 years of experience, including more than 15 years of experience in the life science industry. Ms. Van Hoose joined Dermata Therapeutics, Inc. as the Senior Vice President, Chief Financial Officer in September 2021. Prior to Dermata, Ms. Van Hoose served as Chief Financial Officer of TEGA Therapeutics, Inc., a private biotechnology company, the head of finance for Curzion Pharmaceuticals, Inc., a private, rare disease company, until its acquisition by Horizon Therapeutics plc, as well as at Avelas Biosciences, Inc., a clinical-stage biotechnology company. For over a decade, Ms. Van Hoose held leadership positions of increasing responsibilities at Acadia Pharmaceuticals, Inc., (NASDAQ: ACAD) including Senior Director of Finance and Corporate Controller. Ms. Van Hoose began her career at Deloitte and is a licensed Certified Public Accountant (California active). Ms. Van Hoose earned her B.S. in Accounting at the University of Southern California and M.B.A. in Finance at University of California, Irvine.